Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
3D Slams Toho’s Info Requests as Bid to Justify Defense Measures
3D Investment Partners on April 17 submitted a third response to Toho Holdings’ request for additional information regarding its planned large-scale share purchase, while accusing the drug wholesaler of seeking to justify potential defensive measures. In its latest reply, the…
To read the full story
Related Article
- 3D Seeks Injunction against Toho’s Poison Pill
August 18, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
- 3D Says Toho Share Purchase Is Long-Term Investment, Not Attempt at Control
February 5, 2026
- Toho Seeks Additional Disclosure from 3D over Proposed Share Purchases
January 26, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
- Toho Adopts Poison Pill in Response to 3D’s Rising Stake
November 4, 2025
BUSINESS
- Gilead Files CAR-T Therapy Tecartus in Japan for MCL, B-ALL
August 21, 2026
- Tiger, Gaudi Develop Compact Cell Transport Container
August 21, 2026
- Sawai’s Solo Tenelia Copy Raises Patent Questions Ahead of December Listing
August 21, 2026
- DT-Axis Charts Path to 2nd-Stage DTx Approval with Depression App
August 21, 2026
- Amvuttra Key to Alnylam Japan’s 25%-Plus CAGR Goal through 2030
August 20, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…